ROS1 Gene Rearrangement
7
2
3
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
14.3%
1 terminated out of 7 trials
0.0%
-86.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (7)
REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement